Enzo Biochem, Inc. ENZ NYSE

Enzo Biochem, Inc. (ENZ) reported total assets of $85.76M and total liabilities of $29.65M for fiscal year 2024, resulting in total equity of $56.11M.

The company held $52.37M in cash and short-term investments. Total debt stood at $3.51M, with net debt of $-48.86M. The Debt-to-Equity (D/E) ratio was 0.06 (conservative).

Current ratio is 2.82, indicating strong short-term liquidity. Interest coverage is -49.8x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (39/100) — Total assets $85.76M and equity $56.11M support the company's competitive scale

Overall SharesGrow Score: 36/100 with 0/7 criteria passed.

SHC

Sotera Health Company

$16.03

+0.63%

OLK

Olink Holding AB (publ)

$26.08

+0.31%

CSTL

Castle Biosciences, Inc.

$24.62

+1.03%

GTH

Genetron Holdings Limited

$4.03

+0.12%

FONR

FONAR Corporation

$18.77

+0.05%

STIM

Neuronetics, Inc.

$1.39

-2.80%

BDSX

Biodesix, Inc.

$12.66

+4.28%

SERA

Sera Prognostics, Inc.

$2.18

+1.87%